{"id":5469,"date":"2021-12-01T07:00:00","date_gmt":"2021-12-01T06:00:00","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-presenterade-pa-stora-aktiedagen-stockholm-2021\/"},"modified":"2021-12-01T07:00:00","modified_gmt":"2021-12-01T06:00:00","slug":"stayble-therapeutics-presenterade-pa-stora-aktiedagen-stockholm-2021","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-presenterade-pa-stora-aktiedagen-stockholm-2021\/","title":{"rendered":"Stayble Therapeutics presenterade p\u00e5 Stora Aktiedagen Stockholm 2021"},"content":{"rendered":"<p style=\"text-align:justify;margin-top:12px\"><span><span style=\"font-size:9pt\"><span><span style=\"color:#3b3838\"><span><span style=\"font-family:arial,helvetica,sans-serif\">VD Andreas Gerward presenterade Bolaget, utvecklingen av injektionsbehandlingen STA363 mot kronisk diskrelaterad ryggsm\u00e4rta, samt positiva interimresultat fr\u00e5n den p\u00e5g\u00e5ende fas 2b-studien. <\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<p align=\"left\" style=\"text-align:left\"><span><span style=\"font-size:9pt\"><span><span style=\"font-family:arial,helvetica,sans-serif\"><span style=\"color:#3b3838\">Presentationen fr\u00e5n den 30 november finns tillg\u00e4nglig p\u00e5 f\u00f6ljande l\u00e4nk:<br \/>\n<a href=\"https:\/\/youtu.be\/5isB5oucdJY\" style=\"color:blue;text-decoration:underline\">https:\/\/youtu.be\/5isB5oucdJY<\/a><\/span><\/span><\/span><\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stayble Therapeutics VD Andreas Gerward h\u00f6ll den 30 november 2021 en presentation p\u00e5 Stora Aktiedagen Stockholm 2021, vilket \u00e4r ett evenemang arrangerat av Aktiespararna. Evenemanget, som \u00e4ger rum mellan 29 november och 2 december 2021, \u00e4r ett fysiskt event med studiopublik och webbs\u00e4nds ocks\u00e5 live via Aktiespararnas YouTube-kanal.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5469"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5469"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5469\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}